Reckitt Benckiser Group PLC

Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Johann A. Benckiser in 1823 and is headquartered in Slough, the United Kingdom.

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB)'s shares continue to suffer amid a series of legal challenges related to its baby formula products. The company is facing litigation and significant financial penalties due to allegations surrounding the safety and marketing of its infant nutrition products.

Could Reckitt spin out baby formula wing following Enfamil crisis?

Reckitt Benckiser saw modest gains on Monday, following the share-price slide that erased some £5.6 billion ($7.1 billion) of market value.

Reckitt Benckiser sees modest bounce following $7.1 billion market-cap wipeout

Reckitt said on Monday that many cases had been filed against baby formula makers in general, but it was unclear how many directly related to its unit's Enfamil product.

Reckitt says many cases filed against baby formula makers

Reckitt Beckinser Group said Friday it will seek to overturn a court ruling this week that awarded $60 million in damages to the family of a baby that died after being fed Enfamil infant formula, made by the British conglomerate's Mead Johnson Nutrition unit.

Enfamil maker vows to fight $60 million baby-formula verdict

The rout came after it was reported that an Illinois jury ordered the company's Mead Johnson unit to pay $60 million in compensation related to the death of a premature baby fed Enfamil.

Reckitt Benckiser Sheds Nearly $7 Billion in Market Value After Infant-Formula Verdict

An Illinois jury has ordered Reckitt Benckiser unit Mead Johnson to pay $60 million to the mother of a premature baby who died of an intestinal disease after being fed the company's Enfamil baby formula.

Reckitt unit hit with $60 million verdict in Enfamil baby formula case in Illinois

Ambev

AstraZeneca

Alibaba

Baidu

British American Tobacco

Anheuser-Busch InBev

GlaxoSmithKline

Imperial Brands PLC

JD.com

Kao Corp

Kone Oyj

Medtronic

Nestle SA

Omron Corp

Pernod Ricard SA

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The March 2024 Heat Map

Reckitt Benckiser Group plc (RBGPF) Q4 2023 Earnings Call Transcript

Shares in the Nurofen maker Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) fell 11% with the market spooked by its fourth-quarter sales miss and a £55 million revenue hit related to compliance issues at two of its Middle East operations. At 11.05 am, the stock was off 654p at 5,184p after the company revealed the trading drag was the result of lower-than-expected demand for cold and flu remedies and voluntary recall of its Nutramigen infant formula.

Reckitt Benckiser shares drop 11% after sales miss and Middle East 'compliance issues'

Reckitt Benckiser Group shares opened 7% lower after the Anglo-Dutch consumer products group's fourth-quarter performance fell short of expectations, and an understatement in trade spend that affected its full-year net revenue figure. This underperformance was attributed to reduced sales of cold and flu products during the season.

Reckitt shares tumble 7% on Q4 miss and revenue restatement

Reckitt Benckiser posted a sharp drop in its profits for 2023, as higher prices failed to offset lower sales, in a “grim” set of results that put the company on course for its sharpest share price drop in years.

Reckitt Benckiser Profits Hit by Sales Slowdown, Charge

Consumer goods group Reckitt missed fourth-quarter like-for-like net sales expectations, it said on Wednesday, citing declining sales of cold and flu season products.

Reckitt posts like-for-like net sales drop as fewer people buy flu medication

Any hopes that Taylor Wimpey might 'surprise on the upside' have seemingly been dashed by the CMA probe announced this week

Just Eat, Reckitt Benckiser, Taylor Wimpey in focus on Wednesday

Reckitt Benckiser needs to deliver improving volumes when it reports next week, according to Mark Britzman. “Third-quarter results disappointed and the concern remains that consumers have yet to fully digest higher prices,” he adds.

Reckitt Beckinser's volumes key in next week's update

Shares of Reckitt Benckiser have underperformed in recent years, and they now trade at a meaningful discount to global peers. Performance has been somewhat lumpy due to various one-time, non-company-specific factors, but growth is roughly landing where I thought it could at previous coverage. At around 17x EPS, Reckitt trades at a discount to both is historical average and global peers, and the stock looks priced for attractive medium-term returns.

Reckitt Benckiser: Undervalued With Sound Growth Prospects

The company said that most, if not all, of the possibly contaminated product has already been consumed.

Reckitt Benckiser unit recalls possibly contaminated baby formula powder, FDA says

Reckitt Benckiser Group's Mead Johnson Nutrition (MJN) is voluntarily recalling select batches of Nutramigen Powder from the U.S. market due to a possibility of contamination with Cronobacter sakazakii in product sampled outside the U.S, the U.S. Food and Drug Administration on Sunday.

Reckitt's Mead Johnson Nutrition recalls baby formula powder from US, FDA says

Citi has revised down its forecast for Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB), reflecting a more cautious assessment of prospects for the consumer goods giant, particularly in the short term. Citi has reduced its earnings per share (EPS) estimates for Reckitt for the years 2023 and 2024.

Reckitt Benckiser forecasts trimmed by US influential investment bank

Indivior PLC

Indivior PLC (LSE:INDV, NASDAQ:INDV) has won a case in the High Court against it and former parent Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) after being hit by a lawsuit over the Suboxone branded opioid addiction drug.  In September, Wirral Council filed a claim that Indivior had made misleading or dishonest statements regarding an alleged fraudulent scheme to the market for its Suboxone products in published information relating, violating the Financial Services and Markets Act 2000.

Indivior, Reckitt Benckiser win round one of high court battle over Suboxone anti-opioid claim

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) chairman Chris Sinclair will step down next year and be replaced by former Sky chief executive Jeremy Darroch, making a 12-month clean sweep at the top of the Vanish and Cilit Bang maker.  Sinclair will have served a nine-year term on the board, including six as chair, by the time of the annual shareholder meeting next May, when he will hand over the role.

BANG and the board is done: Reckitt Benckiser completes clean sweep of C-suite

Amcor Plc

Diageo

Legal & General Group PLC

LyondellBasell Industries

Smith & Nephew

Unilever

For weeks, I have pounded the table about the historic opportunity in REITs. The fundamentals were clear that now was the best time in 14 years to buy REITs. Last week, stocks ripped 6% higher, and REITs soared 9%, powered by falling rates that were the only reason REITs had fallen. Today, there is another Warren Buffett-style "fat pitch" opportunity staring at you in plain sight. UK Stocks are trading at 10X earnings and 7X cash-adjusted earnings, a 30% historical discount.

9 Once-In-A Lifetime Blue-Chip Opportunities Yielding As Much As 10%

Reckitt Benckiser has struggled to consistently exploit its portfolio of premium brands and return to its historical growth trajectory. The company's third-quarter performance was impacted by foreign exchange headwinds, but this does not necessarily indicate underlying weakness. The lack of consistency in Reckitt's earnings growth strategy has affected its fair valuation, although it has the potential for strong business performance.

Reckitt Benckiser: Not A Bargain Despite Its Potential

Reckitt Benckiser reported mediocre third quarter results and provided a strategy update recently. While that strategy update was mostly a reaffirmation that Reckitt Benckiser is positioned well in a growing market, it announced a new share buyback program. While the company is continuing to struggle, I still see the business having a wide economic moat as well as the stock being undervalued.

Reckitt Benckiser: Still Optimistic For The Long Run

Investors are turning defensive in the consumer stocks sector, according to JP Morgan with evidence from the latest quarterly earnings season suggesting specific equity stories are now in vogue. Growth slowed with a volumes recovery languishing and earnings momentum negative with most downside from Spirits.

Reckitt and Diageo favoured by JP Morgan as investors seek 'safety' in consumer staples

Not even the start of a £1 billion ($1.21 billion) buyback program could save shares of Reckitt RKT, -4.83% on Wednesday, as they dropped nearly 7% after the consumer goods group missed revenue expectations.

News for Reckitt Benckiser Group PLC Stock (RBGLY)